+Compare
CABA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
801.28M

CABA Price Prediction, Cabaletta Bio AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CABA with price predictions
07:00 PM EST Dec 05, 2023

CABA's RSI Indicator ascends from oversold territory

The RSI Indicator for CABA moved out of oversold territory on November 29, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In of the 13 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for CABA crossed bullishly above the 50-day moving average on November 09, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 205 cases where CABA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where CABA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on November 28, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CABA turned negative on November 28, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .

CABA moved below its 50-day moving average on December 06, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CABA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.646) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (330.425).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

CABA is expected to report earnings to rise 5.86% to -39 cents per share on March 14

Cabaletta Bio CABA Stock Earnings Reports
Q4'23
Est.
$-0.39
Q3'23
Beat
by $0.03
Q2'23
Beat
by $0.07
Q1'23
Beat
by $0.03
Q4'22
Missed
by $0.05
The last earnings report on November 09 showed earnings per share of -37 cents, beating the estimate of -40 cents. With 1.78M shares outstanding, the current market capitalization sits at 801.28M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 27%. IVBT experienced the highest price growth at 1,413%, while IBIO experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2929 Arch Street
Phone
+1 267 759-3100
Employees
60
Web
https://www.cabalettabio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMILX9.840.01
+0.10%
Putnam Multi-Asset Income R5
TEEAX12.44N/A
N/A
RBC Small Cap Core A
CAPRX7.92N/A
N/A
Federated Hermes Capital Income R
EAROX23.90-0.02
-0.08%
First Eagle Overseas R3
TLGUX22.17-0.07
-0.31%
Morgan Stanley Pathway Large Cap Eq

CABA and

Correlation & Price change

A.I.dvisor tells us that CABA and CDTX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CABA and CDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-5.69%
CDTX - CABA
33%
Poorly correlated
-3.72%
ORMP - CABA
32%
Poorly correlated
+3.30%
ICVX - CABA
32%
Poorly correlated
-1.54%
PSTX - CABA
29%
Poorly correlated
+2.34%
GRTS - CABA
29%
Poorly correlated
+9.09%
More